These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16436183)

  • 21. GABA systems, benzodiazepines, and substance dependence.
    Malcolm RJ
    J Clin Psychiatry; 2003; 64 Suppl 3():36-40. PubMed ID: 12662132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem.
    Follesa P; Mancuso L; Biggio F; Cagetti E; Franco M; Trapani G; Biggio G
    Neuropharmacology; 2002 Feb; 42(2):191-8. PubMed ID: 11804615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Provisional mapping of quantitative trait loci for chronic ethanol withdrawal severity in BXD recombinant inbred mice.
    Crabbe JC
    J Pharmacol Exp Ther; 1998 Jul; 286(1):263-71. PubMed ID: 9655868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rostroventral caudate putamen involvement in ethanol withdrawal is influenced by a chromosome 4 locus.
    Chen G; Buck KJ
    Genes Brain Behav; 2010 Oct; 9(7):768-76. PubMed ID: 20608999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limbic circuitry activation in ethanol withdrawal is regulated by a chromosome 1 locus.
    Buck KJ; Chen G; Kozell LB
    Alcohol; 2017 Feb; 58():153-160. PubMed ID: 27989609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic dissection of quantitative trait loci specifying sedative/hypnotic sensitivity to ethanol: mapping with interval-specific congenic recombinant lines.
    Bennett B; Beeson M; Gordon L; Carosone-Link P; Johnson TE
    Alcohol Clin Exp Res; 2002 Nov; 26(11):1615-24. PubMed ID: 12436049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.
    Depoortere H; Zivkovic B; Lloyd KG; Sanger DJ; Perrault G; Langer SZ; Bartholini G
    J Pharmacol Exp Ther; 1986 May; 237(2):649-58. PubMed ID: 2871178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of a novel mouse genotype to model acute benzodiazepine withdrawal.
    Metten P; Buck KJ; Merrill CM; Roberts AJ; Yu CH; Crabbe JC
    Behav Genet; 2007 Jan; 37(1):160-70. PubMed ID: 17226103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
    Doyno CR; White CM
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S114-S128. PubMed ID: 34396551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the GABA(A)beta2, GABA(A)alpha6, GABA(A)alpha1 and GABA(A)gamma2 receptor subunit genes cluster in drug responses and the development of alcohol dependence.
    Loh EW; Ball D
    Neurochem Int; 2000; 37(5-6):413-23. PubMed ID: 10871693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection for pentobarbital withdrawal severity: correlated differences in withdrawal from other sedative drugs.
    Kliethermes CL; Metten P; Belknap JK; Buck KJ; Crabbe JC
    Brain Res; 2004 May; 1009(1-2):17-25. PubMed ID: 15120579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal.
    Griffiths RR; Sannerud CA; Ator NA; Brady JV
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1199-208. PubMed ID: 1312162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention.
    Harris JT; Roache JD; Thornton JE
    Alcohol Alcohol; 2000; 35(4):319-23. PubMed ID: 10905994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethanol tolerance and withdrawal responses in GABA(A) receptor alpha 6 subunit null allele mice and in inbred C57BL/6J and strain 129/SvJ mice.
    Homanics GE; Le NQ; Kist F; Mihalek R; Hart AR; Quinlan JJ
    Alcohol Clin Exp Res; 1998 Feb; 22(1):259-65. PubMed ID: 9514316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Abuse potential during use and withdrawal psychosis after treatment with the hypnotic zolpidem (Stilnoct)].
    Bruun TG
    Ugeskr Laeger; 1993 Aug; 155(35):2711-3. PubMed ID: 7786333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying genes for alcohol and drug sensitivity: recent progress and future directions.
    Crabbe JC; Phillips TJ; Buck KJ; Cunningham CL; Belknap JK
    Trends Neurosci; 1999 Apr; 22(4):173-9. PubMed ID: 10203855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seizure following sudden zolpidem withdrawal.
    Cubała WJ; Landowski J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):539-40. PubMed ID: 16950552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gaboxadol -- a different hypnotic profile with no tolerance to sleep EEG and sedative effects after repeated daily dosing.
    Ebert B; Anderson NJ; Cremers TI; Rasmussen S; Vogel V; Fahey JM; Sánchez C
    Pharmacol Biochem Behav; 2008 Jul; 90(1):113-22. PubMed ID: 18304623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic determinants of severity of acute withdrawal from diazepam in mice: commonality with ethanol and pentobarbital.
    Metten P; Crabbe JC
    Pharmacol Biochem Behav; 1999 Jul; 63(3):473-9. PubMed ID: 10418790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reciprocal congenics defining individual quantitative trait Loci for sedative/hypnotic sensitivity to ethanol.
    Bennett B; Beeson M; Gordon L; Johnson TE
    Alcohol Clin Exp Res; 2002 Feb; 26(2):149-57. PubMed ID: 11964553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.